TABLE 1.
Group | Strain | Serotype | MIC (μg/ml)a
|
Amino acid motifb
|
PCR resultc
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PC | CTX | CPDX | CDTR | CFDN | CCL | S T M K | A H S S N V | L K S G T | pbp1a | pbp2b | |||
None | 1/E9 | 15 | 0.031 | 0.031 | 0.125 | 0.016 | 0.125 | 1 | –––– | –––––– | ––––– | − | − |
2/HSB1 | 15 | 0.031 | 0.031 | 0.125 | 0.031 | 0.125 | 2 | –––– | V––––– | ––––– | − | − | |
3/YO42 | 3 | 0.031 | 0.063 | 0.125 | 0.031 | 0.125 | 1 | –––– | –––––– | ––––– | − | − | |
4/HSC21 | 6 | 0.031 | 0.063 | 0.125 | 0.031 | 0.25 | 1 | –––– | –––––– | ––––– | − | − | |
5/H48 | 19 | 0.031 | 0.063 | 0.125 | 0.031 | 0.25 | 1 | –––– | –––––– | ––––– | − | − | |
I | 6/HSB5 | 3 | 0.008 | 0.125 | 0.5 | 0.031 | 0.25 | 2 | –––– | –––––– | ––––A | − | − |
7/T37 | 6 | 0.008 | 0.125 | 0.25 | 0.031 | 0.25 | 2 | –––– | –––––– | ––––A | − | − | |
8/TJ24 | 9 | 0.016 | 0.125 | 0.25 | 0.031 | 0.25 | 1 | –––– | –––––– | ––––A | − | − | |
9/E13 | 9 | 0.016 | 0.25 | 0.5 | 0.031 | 0.25 | 2 | –––– | –––––– | ––––A | − | − | |
II | 14/TO22 | 19 | 0.031 | 0.063 | 0.25 | 0.063 | 0.125 | 0.5 | –––– | –L–––– | V–––– | − | − |
17/SU1 | 19 | 0.063 | 0.125 | 0.25 | 0.016 | 0.25 | 1 | –––– | –L–––– | V–––– | − | − | |
21/H3 | 10 | 0.031 | 0.125 | 0.25 | 0.063 | 0.125 | 1 | –––– | –L–––– | ––––– | − | − | |
16/MA37 | 23 | 0.063 | 0.125 | 0.25 | 0.125 | 0.25 | 1 | –––– | VL–––– | ––––– | − | − | |
22/H23 | 14 | 0.031 | 0.063 | 0.25 | 0.063 | 0.25 | 1 | –––– | VL–––– | ––––– | − | − | |
III | 11/KM99 | 3 | 0.031 | 0.125 | 0.5 | 0.063 | 0.25 | 0.5 | –A–– | –––––– | ––––– | − | − |
15/HSC9 | 3 | 0.031 | 0.125 | 0.5 | 0.125 | 0.25 | 1 | –A–– | –––––– | ––––– | − | − | |
18/TJ41 | 3 | 0.031 | 0.125 | 0.5 | 0.063 | 0.25 | 2 | –A–– | –––––– | ––––– | − | − | |
23/H69 | 3 | 0.031 | 0.25 | 0.25 | 0.063 | 0.25 | 1 | –A–– | –––––– | ––––– | − | − | |
25/S19 | 3 | 0.031 | 0.125 | 0.5 | 0.125 | 0.25 | 1 | –A–– | –––––– | ––––– | − | − | |
IV | 34/H31 | 6 | 1 | 0.5 | 1 | 0.5 | 4 | 32 | –A–– | –––––– | V–––– | + | + |
36/Z21 | 6 | 2 | 0.5 | 2 | 0.5 | 8 | 64 | –A–– | –––––– | V–––– | + | + | |
37/H28 | 19 | 1 | 0.5 | 2 | 0.5 | 2 | 64 | –A–– | –––––– | V–––– | + | + | |
38/KM90 | 19 | 2 | 0.5 | 2 | 0.5 | 4 | 64 | –A–– | –––––– | V–––– | + | + | |
39/Z13 | 19 | 2 | 0.5 | 1 | 0.5 | 4 | 64 | –A–– | –––––– | V–––– | + | + | |
40/H29 | 23 | 1 | 0.5 | 2 | 0.5 | 4 | 64 | –A–– | –––––– | V–––– | + | + | |
41/B99 | 23 | 1 | 0.5 | 2 | 0.5 | 4 | 64 | –A–– | –––––– | V–––– | + | + | |
42/H0 | 14 | 4 | 1 | 4 | 1 | 8 | 64 | –A–– | –––––– | V–––– | + | + | |
27/S46 | 23 | 0.5 | 0.5 | 1 | 0.25 | 2 | 32 | –A–– | –––––– | V–––– | − | + | |
1A22/HA5 | 6 | 0.25 | 0.5 | 1 | 0.25 | 2 | 16 | –A–– | –––––– | V–––– | − | + | |
V | 20/SHA3 | 19 | 2 | 4 | 16 | 4 | 32 | 64 | –A–– | V––––– | V–––– | + | + |
29/KK133 | 23 | 2 | 8 | 16 | 4 | 32 | 64 | –AF– | –––––– | V–––– | + | + | |
30/NG44 | 23 | 2 | 2 | 16 | 2 | 16 | 64 | –AF– | –––––– | V–––– | + | + | |
31/KU5 | 23 | 1 | 2 | 8 | 2 | 8 | 64 | –AF– | –––––– | V–––– | + | + | |
32/KU81 | 19 | 4 | 4 | 16 | 2 | 16 | 64 | –AF– | –––––– | V–––– | + | + | |
33/AK5 | 14 | 0.125 | 4 | 16 | 2 | 2 | 8 | –AF– | –––––– | V–––– | + | − |
Susceptibilities to PC, CTX, cefpodoxime (CPDX), cefditoren (CDTR), cefdinir (CFDN), and cefaclor (CCL) were determined by previously described methods (1).
Only amino acid residues differing from PBP 2X conserved motif sequences of the PSSP strain R6 are shown. Conserved amino acid motifs are underlined.
Altered PBP genes were detected by PCR as described previously (29). +, altered; −, not altered.